You have heard the names. Ozempic. Wegovy. Mounjaro. Zepbound. A friend lost weight on one of them, an ad told you another could change your life, and somewhere along the way someone said the word “GLP-1” like you should already know what it meant.
You do not. Not yet. And that is fair, because the category went from medical-journal niche to dinner-table topic in about three years. Most articles still sound like they were written for doctors.
This guide is the plain-English version. You will learn what GLP-1 is, what semaglutide and tirzepatide do, who the medications are for, and how access actually works in the US in 2026.
Key takeaways
- GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after meals.
- GLP-1 medications copy that hormone and keep it active for much longer.
- Semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro) lead the category in 2026.
- Average weight loss is about 14.9% on Wegovy and 22.5% on the highest dose of Zepbound.
- The class also lowers heart attack and stroke risk, with growing data in kidney disease and sleep apnea.
What readers want to figure out
Most people land on a “what is GLP-1” page with the same questions. They want a clear answer without a textbook chapter. They are trying to tell semaglutide and tirzepatide apart and pick the one that fits their situation. They want to know how much weight people actually lose and what the side effects feel like. They want a real read on cost, insurance, and whether compounded versions are still available in 2026. And they want to know how to get a prescription if they decide it is worth pursuing.
This guide answers each of those questions in order.
What “GLP-1” actually means
GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine releases after you eat. It is part of a group called incretins, which help your body manage blood sugar after meals.
Native GLP-1 only sticks around for a couple of minutes before an enzyme called DPP-4 breaks it down. That short life is why your body makes more of it every time you eat.
GLP-1 medications are built to look like the hormone but resist that enzyme, so a single dose can keep working for a full week.
How GLP-1 medications work
GLP-1 medications copy the hormone and bind to the same receptors your body already uses. Once attached, they trigger four effects that add up to lower blood sugar and a smaller appetite (Müller 2019).
- They tell the pancreas to release more insulin when blood sugar is high.
- They tell the pancreas to release less glucagon, the hormone that raises blood sugar.
- They slow how fast food leaves the stomach, so you feel full longer.
- They quiet appetite signals in the brain, including what patients often call “food noise.”
Tirzepatide does all of that and one more thing. It also activates a second hormone receptor called GIP, which is why people often see bigger weight loss on it.
GLP-1 medications you will see in 2026
Four GLP-1 medications make up almost every prescription written in the US. Two of them, semaglutide and tirzepatide, do most of the work.
| Drug | Brand names | Approved use | How it is taken |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Type 2 diabetes; obesity; lower heart attack and stroke risk | Weekly shot or daily pill |
| Tirzepatide | Mounjaro, Zepbound | Type 2 diabetes; obesity; obstructive sleep apnea | Weekly shot |
| Liraglutide | Victoza, Saxenda | Type 2 diabetes; obesity (Saxenda) | Daily shot |
| Dulaglutide | Trulicity | Type 2 diabetes; lower heart attack and stroke risk | Weekly shot |
The rest of this guide focuses on the two leaders, since they are what most people are weighing.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. It comes in three brand names that all carry the same active ingredient.
Ozempic is a weekly shot prescribed for adults with type 2 diabetes. Wegovy is the same drug at higher doses, prescribed for adults with obesity, and now also for lowering heart attack and stroke risk in adults with obesity and known heart disease (Lincoff 2023). Rybelsus is a daily oral pill version of semaglutide for type 2 diabetes.
In the STEP 1 trial, adults on Wegovy lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo (Wilding 2021). That study is the one most cost and outcome questions trace back to.
What is tirzepatide?
Tirzepatide is the newer drug, made by Eli Lilly. It is a once-weekly shot, and it activates two hormone receptors instead of just one.
Mounjaro is the brand name prescribed for adults with type 2 diabetes. Zepbound is the same drug at obesity doses, and in December 2024 the FDA also approved it for adults with obesity and obstructive sleep apnea, the first medication in this class to carry that approval.
In the SURMOUNT-1 trial, adults on the highest tirzepatide dose lost an average of 22.5% of their body weight over 72 weeks, compared with 2.4% on placebo (Jastreboff 2022). A more recent head-to-head trial called SURMOUNT-5 showed tirzepatide outperforming semaglutide on weight loss in adults with obesity (Aronne 2025).
Semaglutide and tirzepatide, side by side
The two drugs share most of their core mechanism. The differences show up in how much weight people tend to lose, the dosing range, and which non-weight benefits each one carries.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Receptors | GLP-1 only | GLP-1 and GIP |
| Average weight loss | 14.9% over 68 weeks (STEP 1) | 22.5% over 72 weeks at top dose (SURMOUNT-1) |
| Dosing range | 0.25 to 2.4 mg weekly | 2.5 to 15 mg weekly |
| Form | Weekly shot or daily pill | Weekly shot |
| Other approved uses | Heart attack and stroke risk reduction | Obstructive sleep apnea in obesity |
| Maker | Novo Nordisk | Eli Lilly |
How much weight people lose on GLP-1
Average numbers are useful, but the spread matters. Some people lose much more than the average. Some lose much less.
In STEP 1, about a third of adults on semaglutide lost more than 20% of their body weight. In SURMOUNT-1, more than half of adults on the highest dose of tirzepatide hit that mark. Response depends on starting weight, how long someone stays on the medication, and how the body handles dose increases.
Weight loss usually shows up in the first few months, then slows. Most studies follow people for 12 to 18 months, which is why providers often talk about treatment in years, not weeks.
Side effects and what to watch for
Most side effects are gut-related, especially during the first weeks while the dose is going up.
Common, usually short-lived
The most reported side effects are nausea, vomiting, diarrhea, constipation, heartburn, and reduced appetite. They tend to ease as the body adjusts. Slow dose increases and small protein-forward meals usually help.
Less common but more serious
Pancreatitis, gallbladder problems, and kidney stress (often from dehydration) show up at low rates in trials and post-market reports. Loss of muscle along with fat is a real concern, which is why doctors often pair GLP-1 use with strength training and high protein intake.
The boxed warning
Both drug labels carry an FDA boxed warning about a rare thyroid tumor called medullary thyroid carcinoma, based on rodent studies. People with a personal or family history of medullary thyroid cancer or a condition called MEN2 should not use these medications.
When to call your doctor
Get medical help quickly if you notice severe stomach pain that does not go away (possible pancreatitis), pain in the upper right belly with nausea or fever (possible gallbladder problem), signs of dehydration like dark urine or dizziness, or a neck lump or trouble swallowing that does not resolve.
For dose-by-dose tactics on managing the rough first weeks, see my guide on peptides.
Who GLP-1 medications are for
Wegovy and Zepbound are prescribed for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, or sleep apnea. Ozempic and Mounjaro are prescribed for adults with type 2 diabetes.
These medications are not for everyone. Pregnancy, a personal or family history of medullary thyroid cancer, MEN2, and a history of pancreatitis are all reasons to avoid them. Talk to your doctor about whether the math works in your case.
What GLP-1 may help beyond weight
The class started as a diabetes drug. The newer story is that the same mechanism appears to help several conditions linked to chronic inflammation and insulin resistance.
Heart
In the SELECT trial, adults with obesity and known cardiovascular disease taking semaglutide had a 20% lower risk of heart attack, stroke, or cardiovascular death over five years (Lincoff 2023). The FDA approved Wegovy for cardiovascular risk reduction in March 2024.
Kidneys
In the FLOW trial, adults with type 2 diabetes and chronic kidney disease taking semaglutide had a 24% lower risk of major kidney events compared with placebo (Perkovic 2024).
Sleep apnea
Zepbound is the first medication in this class with FDA approval for obstructive sleep apnea in adults with obesity, granted in December 2024. Trials in fatty liver disease and Alzheimer’s disease are also active.
Cost and insurance
Brand-name GLP-1 medications carry a high list price, and out-of-pocket cost without coverage is steep. Coverage varies by plan, by drug, and by indication. Many plans cover Ozempic and Mounjaro for type 2 diabetes more readily than Wegovy and Zepbound for obesity.
Manufacturer savings programs, employer coverage updates, and Medicare expansion in 2026 all change the picture often.
Compounded GLP-1 in 2026
When the FDA listed semaglutide and tirzepatide as drugs in shortage, US compounding pharmacies were allowed to make custom versions for patients who could not get the brand-name product. The FDA removed tirzepatide from the shortage list in October 2024 and semaglutide in February 2025.
After those removals, large-scale compounding stopped. Some 503A pharmacies still fill personalized prescriptions when a patient’s specific clinical need is not met by the commercial product, like a patient who needs an allergen-free formulation. Telehealth providers vary in whether they offer brand-name only, 503A, or both.
How to get a GLP-1 prescription
There are two main paths to a prescription in 2026: your doctor or a telehealth provider.
The doctor route works through your primary care office or an obesity medicine specialist. They can write the prescription, your insurance reviews it, and your pharmacy fills it. This works best if you have coverage and an established relationship.
The telehealth route is faster and built around the GLP-1 program from the start. You complete a medical intake online, a licensed clinician reviews it, and the prescription routes to a partner pharmacy. Most reputable providers run regular check-ins and adjust the dose over time.
Bottom line
GLP-1 is a hormone your gut already makes, and GLP-1 medications copy it for longer. Semaglutide and tirzepatide are the two leaders in 2026. The data on weight, cardiovascular risk, kidney disease, and sleep apnea is the strongest reason the category keeps expanding. The next decision is whether the medication, the program, and the cost line up for your situation.
Frequently asked questions
Is GLP-1 the same as Ozempic?
GLP-1 is the hormone, and Ozempic is one specific brand-name medication that copies it. Ozempic contains semaglutide, which is one of several GLP-1 receptor agonists. Wegovy and Rybelsus also contain semaglutide. Mounjaro and Zepbound contain a different drug, tirzepatide, which works on GLP-1 plus a second receptor called GIP. Calling all of them “Ozempic” is a common shortcut, but it is not accurate.
What does GLP-1 stand for?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your small intestine releases after meals. Its job is to help your body manage blood sugar by raising insulin, lowering glucagon, slowing stomach emptying, and reducing appetite. GLP-1 medications are lab-made versions that copy the hormone and resist the enzyme that normally breaks it down within minutes, so they keep working for a full week.
What is the best GLP-1 medication for weight loss?
On average, tirzepatide produces more weight loss than semaglutide. In SURMOUNT-1, adults at the top dose lost about 22.5% of their body weight over 72 weeks, compared with about 14.9% in STEP 1 with semaglutide. The “best” choice still depends on your medical history, side effect tolerance, insurance coverage, and how your body responds. A prescriber who handles weight management can help you weigh which one fits your situation.
What is microdosing GLP-1?
Microdosing means taking a smaller weekly dose than the standard label, often a starter or near-starter dose held long term. It is not an FDA-recognized protocol. Some patients and clinicians use it to limit side effects, hold weight after a successful run, or test tolerance. Evidence is limited to case reports and clinic data, not large trials. Anyone considering it should work with a prescriber who can monitor results.
Can I raise my GLP-1 naturally without medication?
Diet and lifestyle do raise endogenous GLP-1, but the effect is modest compared with medication. High-fiber meals, protein at every meal, fermented foods, and regular exercise all bump GLP-1 release. The increase is real but short-lived and small in size, since native GLP-1 lasts only minutes. Lifestyle is a strong complement to GLP-1 therapy. It is not a one-for-one substitute when medication is clinically indicated.
What is bad about GLP-1 medications?
The main downsides are gut side effects during dose increases, plus rare pancreatitis, gallbladder, and kidney stress risks. The class carries an FDA boxed warning about medullary thyroid cancer from rodent studies. Cost is a barrier when insurance does not cover obesity treatment. Most people regain some weight after stopping, which is why providers treat GLP-1 as long-term medicine. A prescriber who follows your case can help you weigh the trade-offs.
Editorial disclosure and disclaimer
Self Care Voyage is an independent editorial review site. We do not sell, prescribe, compound, or dispense any medication. This article contains affiliate links, which means Self Care Voyage may earn a commission if you sign up with a provider through these links, at no additional cost to you. Our editorial ratings and recommendations are independent and based on public information about each provider. This article is educational, not medical advice. Compounded GLP-1 medications are not FDA-approved, and clinical trial results reported for brand-name GLP-1 medications may not transfer to compounded formulations. Individual results vary. Talk to your doctor before starting any GLP-1 medication, especially if you have a history of thyroid cancer, pancreatitis, gallbladder problems, or are pregnant.
Sources
- Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6812410/
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med.2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- US Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound). December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
